Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02431260 · OUTCOME

Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies · Source last updated 2019-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
nM
Interval / dispersion
Standard Deviation
Time frame
Summary of steady-state PK parameters by dosing regimen at Day 15

What was measured

Minimum observed plasma concentration measured at steady state (Day 15). Study drug was administered with 240 mL of water. Summary of Steady-State, Day 15, was evaluated by dosing regimen.

Analysis population: All enrolled patients who received at least 1 dose of study medication and provided at least 1 plasma sample were included.

Groups in this outcome

INCB054329 Monotherapy - 15 mg QD

INCB054329 Monotherapy

INCB054329 Monotherapy - 15 mg BID

INCB054329 Monotherapy

INCB054329 Monotherapy - 22.5 mg QD

INCB054329 Monotherapy

INCB054329 Monotherapy - 30 mg QD

INCB054329 Monotherapy

INCB054329 Monotherapy - 20 mg BID

INCB054329 Monotherapy

INCB054329 Monotherapy - 22.5 mg BID

INCB054329 Monotherapy

INCB054329 Monotherapy - 25 mg BID

INCB054329 Monotherapy

INCB054329 Monotherapy - Overall Dosing Regimen

INCB054329 Monotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCB054329 Monotherapy - 15 mg QD4
INCB054329 Monotherapy - 15 mg BID5
INCB054329 Monotherapy - 22.5 mg QD4
INCB054329 Monotherapy - 30 mg QD4
INCB054329 Monotherapy - 20 mg BID13
INCB054329 Monotherapy - 22.5 mg BID12
INCB054329 Monotherapy - 25 mg BID7
INCB054329 Monotherapy - Overall Dosing Regimen49

Reported measurements

Source class 1
Values in nM · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
INCB054329 Monotherapy - 15 mg QD0.5381.08Not reportedNot reportedNot reported
INCB054329 Monotherapy - 15 mg BID1.092.45Not reportedNot reportedNot reported
INCB054329 Monotherapy - 22.5 mg QD00Not reportedNot reportedNot reported
INCB054329 Monotherapy - 30 mg QD1.513.02Not reportedNot reportedNot reported
INCB054329 Monotherapy - 20 mg BID54.291.1Not reportedNot reportedNot reported
INCB054329 Monotherapy - 22.5 mg BID14.645Not reportedNot reportedNot reported
INCB054329 Monotherapy - 25 mg BID00Not reportedNot reportedNot reported
INCB054329 Monotherapy - Overall Dosing RegimenNANANot reportedNot reportedDose dependent parameter and overall summary not provided.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.08
        value
        0.538
      2. group Id
        OG001
        spread
        2.45
        value
        1.09
      3. group Id
        OG002
        spread
        0
        value
        0
      4. group Id
        OG003
        spread
        3.02
        value
        1.51
      5. group Id
        OG004
        spread
        91.1
        value
        54.2
      6. group Id
        OG005
        spread
        45
        value
        14.6
      7. group Id
        OG006
        spread
        0
        value
        0
      8. comment
        Dose dependent parameter and overall summary not provided.
        group Id
        OG007
        spread
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      5
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      13
    6. group Id
      OG005
      value
      12
    7. group Id
      OG006
      value
      7
    8. group Id
      OG007
      value
      49
    units
    Participants
description
Minimum observed plasma concentration measured at steady state (Day 15). Study drug was administered with 240 mL of water. Summary of Steady-State, Day 15, was evaluated by dosing regimen.
dispersion Type
Standard Deviation
groups
  1. description
    INCB054329 Monotherapy
    id
    OG000
    title
    INCB054329 Monotherapy - 15 mg QD
  2. description
    INCB054329 Monotherapy
    id
    OG001
    title
    INCB054329 Monotherapy - 15 mg BID
  3. description
    INCB054329 Monotherapy
    id
    OG002
    title
    INCB054329 Monotherapy - 22.5 mg QD
  4. description
    INCB054329 Monotherapy
    id
    OG003
    title
    INCB054329 Monotherapy - 30 mg QD
  5. description
    INCB054329 Monotherapy
    id
    OG004
    title
    INCB054329 Monotherapy - 20 mg BID
  6. description
    INCB054329 Monotherapy
    id
    OG005
    title
    INCB054329 Monotherapy - 22.5 mg BID
  7. description
    INCB054329 Monotherapy
    id
    OG006
    title
    INCB054329 Monotherapy - 25 mg BID
  8. description
    INCB054329 Monotherapy
    id
    OG007
    title
    INCB054329 Monotherapy - Overall Dosing Regimen
param Type
MEAN
population Description
All enrolled patients who received at least 1 dose of study medication and provided at least 1 plasma sample were included.
reporting Status
POSTED
time Frame
Summary of steady-state PK parameters by dosing regimen at Day 15
title
Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329
type
SECONDARY
unit Of Measure
nM

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice